Application of pharmacogenomics and other new technologies to drug development

被引：1
|
作者：
Cabaleiro, Teresa [1 ]
Prieto-Perez, Rocio [1 ]
Ochoa, Dolores [1 ]
Abad-Santos, Francisco [1 ]
机构：
[1] Hosp Univ Princesa, Inst Teofilo Hernando, Inst Invest Sanitaria Princesa IP, Serv Farmacol Clin, Madrid, Spain
来源：
MEDICINA CLINICA | 2013年 / 140卷 / 12期
关键词：
PERSONALIZED MEDICINE; REGULATORY PERSPECTIVE; TOXICOLOGY; CANCER; TOXICOGENOMICS; CHALLENGES; BIOMARKERS; DISCOVERY; PARADIGM; THERAPY;
D O I：
10.1016/j.medcli.2013.02.010
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：558 / 563
页数：6
相关论文
共 50 条
  • [41] Implications of pharmacogenomics for drug development and clinical practice
    Ginsburg, GS
    Konstance, RP
    Allsbrook, JS
    Schulman, KA
    ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (20) : 2331 - 2336
  • [42] Editorial: A New Chapter in Assay and Drug Development Technologies
    Lo, Kevin W. H.
    ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2025, 23 (01) : 1 - 1
  • [43] New technologies around biomarkers and their interplay with drug development
    Frank Dieterle
    Estelle Marrer
    Analytical and Bioanalytical Chemistry, 2008, 390 : 141 - 154
  • [44] Perspectives on the Current State of Pharmacogenomics in Drug Development
    Tamaoki, Mieko
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2009, 129 (01): : 135 - 145
  • [45] Pharmacogenomics: A Genetic Approach to Drug Development and Therapy
    Qahwaji, Rowaid
    Ashankyty, Ibraheem
    Sannan, Naif S.
    Hazzazi, Mohannad S.
    Basabrain, Ammar A.
    Mobashir, Mohammad
    PHARMACEUTICALS, 2024, 17 (07)
  • [46] Can pharmacogenomics make a difference in drug development?
    Fred D. Ledley
    Nature Biotechnology, 1999, 17 : 731 - 731
  • [47] Pharmacogenomics to Revive Drug Development in Cardiovascular Disease
    Dube, Marie-Pierre
    de Denus, Simon
    Tardif, Jean-Claude
    CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (01) : 59 - 64
  • [48] Pharmacogenomics to Revive Drug Development in Cardiovascular Disease
    Marie-Pierre Dubé
    Simon de Denus
    Jean-Claude Tardif
    Cardiovascular Drugs and Therapy, 2016, 30 : 59 - 64
  • [49] Payer perspectives on pharmacogenomics testing and drug development
    Epstein, Robert S.
    Frueh, Felix W.
    Geren, Dawn
    Hummer, Doris
    McKibbin, Scott
    O'Connor, Susan
    Randhawa, Gurvaneet
    Zelman, Benjamin
    PHARMACOGENOMICS, 2009, 10 (01) : 149 - 151
  • [50] New technologies around biomarkers and their interplay with drug development
    Dieterle, Frank
    Marrer, Estelle
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2008, 390 (01) : 141 - 154
12345